|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | Grand Central Station, PO Box 4777 |
Address2 |
|
City | New York |
State | NY |
Zip Code | 10163 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104060-12
|
||||||||
|
6. House ID# 432920001
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Dustin Watson |
Date | 4/15/2022 4:19:13 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General Parkinson's disease information about symptoms, triggers, health coverage, health costs, social determinants of health related to Parkinson's disease and data collection, research, and health access for underserved communities
Advocating for Parkinson's patients during COVID-19, including extension of health care subsidies
Advocating for proposed repeal of Department of Health and Human Services rule entitled Securing Updated and Necessary Statutory Evaluations Timely
Advocating on for more specific Parkinson's disease ICD-10-CM codes to assist in the continuation and coordination of care and allow researchers to have data to study the disease progression
Advocating for expanding access to care via telehealth
Advocating for rulemaking to ensure standards in the Americans with Disabilities Act (ADA) are applied to the internet
Advocating for reauthorization of CDCs National Neurological Conditions Surveillance System (NNCSS)
S. 3799, the Prepare for and Respond to Existing Viruses, Emerging New Threats (PREVENT), and Pandemics Act
S. 253, the Cannabidiol and Marihuana Research Expansion Act
S. 1467/H.R. 2916, the VA Medicinal Cannabis Research Act
H.R. 5657, the Medical Marijuana Research Act
H.R. 3617, the Marijuana Opportunity Reinvestment and Expungement Act
H.R. 2916/S. 1467, the VA Medical Cannabis Research Act of 2021
H.R. 3105, the Common Sense Cannabis Reform for Veterans, Small Businesses, and Medical Professionals Act
S. 1670/H.R. 3321, the Credit for Caring Act
H.R. 253, the Adult Day Care Center Enhancement Act
S. 464/H.R. 2163, the Safe Step Act
H.R. 3013, the COVID Vaccine Transportation Access Act
H.R. 2503, the Social Determinants Accelerator Act of 2021
H.R. 6000, the Cures 2.0 Act
H.R. 4521, the America COMPETES Act of 2022
H.R. 2565/S. 2952, the FDA Modernization Act of 2021
H.R. 5435 BRAIN Act of 2021
S. 3427, the Neuroscience Center of Excellence Act of 2021
H.R. 6584, the DEPICT Act
S.Res. 577: A resolution designating April 2022 as "Parkinson's Awareness Month"
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Office of Science & Technology Policy (OSTP), Justice - Dept of (DOJ), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Nora |
Eigenbrodt |
|
|
|
Megan |
May |
|
|
|
Ted |
Thompson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Expanding Medicare benefits to include dental, hearing, and vision
Extending and making permanent COVID-19 telehealth flexibilities
Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, capping out-of-pocket costs and smoothing, and streamlining prior authorization processes
Advocating for improvements to Medicare Part C and Part D proposed rule
H.R. 4417, the Capping Drug Costs for Seniors Act
S. 2327, the Seniors Prescription Drug Relief Act
S. 828/H.R. 432, the Mental Health Access Improvement Act of 2021
H.R. 2080, the Seniors Access to Vaccine Ensured Act of 2021
H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act
H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021
S. 2061/H.R. 4058, the Telemental Health Care Access Act of 2021
S. 1512/H.R. 2903, the Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2021
S. 3593, the Telehealth Extension and Evaluation Act
H.R. 6202, the Telehealth Extension Act of 2021
H.R. 1332/S. 368, the Telehealth Modernization Act
H.R. 366, the Protecting Access to Post-COVID-19 Telehealth Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
Director of Government Relations |
|
Mason |
Zeagler |
|
|
|
Megan |
May |
|
|
|
Nora |
Eigenbrodt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
General education on triggers of Parkinson's disease, including TCE, paraquat, and other chemicals.
Supporting creation of Neuroscience Center of Excellence at FDA.
S. 3427, the Neuroscience Center of Excellence Act
H.R. 5435, the BRAIN Act
H.R. 6000, the Cures 2.0 Act
S. 3282, the Protect Americas Children from Toxic Pesticides Act
H.R. 3967 Honoring our Promise to Address Comprehensive Toxics (PACT) Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
Director of Government Relations |
|
Megan |
May |
|
|
|
Ted |
Thompson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2022 Appropriation bills including Parkinson's research funding requests for:
Department of Defense
National Institute of Health
Centers for Disease Control and Prevention
Food and Drug Administration
FY 2023 Appropriations bills including Parkinson's research funding requests for:
Department of Defense
National Institute of Health
Centers for Disease Control and Prevention
Food and Drug Administration
Department of Veterans Affairs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
|
|
Megan |
May |
|
|
|
Ted |
Thompson |
|
|
|
Mason |
Zeagler |
|
|
|
Nora |
Eigenbrodt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
General education around pharmaceuticals related to Parkinson's disease
Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols
Prescription Drug User Fee Act
H.R. 4417, the Capping Drug Costs for Seniors Act
H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021
S. 2327, the Seniors Prescription Drug Relief Act
H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021
H.R. 2163, the Safe Step Act
H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
Director of Government Relations |
|
Mason |
Zeagler |
|
|
|
Megan |
May |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
General education regarding the importance of the Department of Defense medical research programs for military service personnel and Veterans living with Parkinson's disease.
Inclusion of Parkinson's disease and PD-related diseases as presumptive conditions when military Veterans are exposed to associated toxins
Support for VA's Parkinson's Disease Research, Education and Clinical Center
H.R. 3967, the Honoring Our PACT Act
H.R. 6774, the Boxing Therapy for Parkinson's Access Act of 2022
H.R. 6659/S. 3541, the Health Care for Burn Pit Veterans Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
Director of Government Relations |
|
Megan |
May |
|
|
|
Ted |
Thompson |
|
|
|
Mason |
Zeagler |
|
|
|
Nora |
Eigenbrodt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
General education regarding environmental triggers of neurological disease and support for more research.
S. 3283, the Protect America's Children from Toxic Pesticides Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dustin |
Watson |
|
Director of Government Relations |
|
Megan |
May |
|
|
|
Ted |
Thompson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |